Provider profile
Novo Nordisk direct-access programs — compounded GLP-1 pricing & profile
Captured pricing, fees, pharmacy disclosure, and evidence status — provider-reported, not checkout-verified.
Novo Nordisk direct-access programs is a manufacturer / brand-access channel — a channel for FDA-approved products, profiled here for context but never ranked as a compounded provider. Compounded and approved products are different regulatory classes and are not compared on the same axis.
Captured pricing
Novo Nordisk direct-access programs does not publish a single flat compounded price in the captured data. Semaglutide: Wegovy/Ozempic self-pay starts at $149/month for eligible oral doses; selected pen offers start at $199 for introductory fills, then standard pricing generally $349/month for Wegovy pens; dose-specif…. Tirzepatide: Not applicable. Because no stable per-plan figure was captured, Novo Nordisk direct-access programs is shown for transparency but is not placed in the ranked pricing tables. Confirm current pricing on the provider's own page before relying on any figure.
Fees, pharmacy, and disclosure
| Category | Manufacturer / brand-access channel |
| Current status | Active but evidence incomplete |
| Membership / program fee | Medication price |
| Pharmacy disclosure | Not verified |
| Material relationship | No known material relationship — publisher attested 2026-07-20; independent verification not performed |
| Evidence status | PROVIDER REPORTED · confidence high |
| Last checked | 2026-07-20 |
| Official source | provider page |
Capture note: Separate obesity and diabetes product eligibility and labeling; do not treat every semaglutide product as interchangeable.
How to read this channel
As a manufacturer or brand-access channel, Novo Nordisk direct-access programs supplies FDA-approved product, which carries premarket-reviewed manufacturing that compounded products do not. If you have insurance coverage or qualify for a manufacturer cash-pay program, an approved product can be cheaper and better-evidenced than any compounded option — price that first. See the brand-vs-compounded cost guide. This channel is never ranked against compounded providers.
Frequently asked questions
How much does Novo Nordisk direct-access programs charge for compounded GLP-1?
Novo Nordisk direct-access programs did not publish a single flat compounded price in the captured data — wegovy/ozempic self-pay starts at $149/month for eligible oral doses; selected pen offers start at $199 for introductory fills, then standard pricing generally $349/month for wegovy pens; dose-specif…. Confirm current pricing directly with the provider, and compute effective monthly cost at your maintenance dose before comparing.
Does Novo Nordisk direct-access programs charge a membership fee?
As a brand-access channel, its fee structure differs from compounded telehealth. Captured: Medication price. A required membership belongs in the effective-cost math, so add it in before comparing Novo Nordisk direct-access programs to any flat-priced provider.
Is Novo Nordisk direct-access programs's pricing verified?
No. Novo Nordisk direct-access programs's evidence status is provider reported (confidence high); figures are provider-reported or independently calculated, not checkout-verified, and its pharmacy disclosure is "not verified". Treat every figure as a starting point to confirm, not a guarantee.